Royalty Pharma Market Sentiment

Market sentiment signals for Royalty Pharma (RPRX): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 2.9% short float

Options Flow▲ 0.00 P/C ratio

Insider Activity▼ Net Seller (30d)

Analyst Consensus

Buy

10 analysts

Options Flow (P/C)

0.00

More calls — Bullish

667 calls · 0 puts

Avg Consensus PT

$56

-12.8%

Highest Price Target

$68

+6.7%

TD Cowen

Lowest Price Target

$38

-40.4%

B of A Securities

Short Interest

2.9%

Rising — Bearish

Insider Activity (30d)

Net Seller

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Oct 7, 2026	Morgan Stanley	Terence Flynn—	+5.1%	$65 → $67	Maintained	Overweight
Sep 8, 2026	TD Cowen	Michael Nedelcovych—	+6.7%	$65 → $68	Maintained	Buy
Aug 7, 2026	JP Morgan	Chris Schott—	-2.7%	$58 → $62	Maintained	Overweight
Jul 13, 2026	TD Cowen	Steve Scala—	+2.0%	$50 → $65	Maintained	Buy
May 7, 2026	Citigroup	Geoff Meacham—	+3.5%	$50 → $66	Maintained	Buy
May 7, 2026	JP Morgan	Chris Schott—	-9.0%	$50 → $58	Maintained	Overweight
Apr 21, 2026	UBS	Ashwani Verma—	-10.6%	$51 → $57	Maintained	Buy
Apr 10, 2026	Morgan Stanley	Terence Flynn—	-1.2%	$61 → $63	Maintained	Overweight
Jan 30, 2026	UBS	Ashwani Verma—	-23.1%	$38 → $49	Upgrade	Neutral→Buy
Jan 27, 2026	Citigroup	Geoff Meacham—	-21.6%	$48 → $50	Maintained	Buy
Dec 11, 2025	TD Cowen	Steve Scala—	-29.4%	$42 → $45	Maintained	Buy
Oct 10, 2025	Morgan Stanley	Terence Flynn—	-15.3%	$55 → $54	Maintained	Overweight
Sep 30, 2025	Goldman Sachs	Asad Haider —	-34.1%	$42	Initiate	Buy
Jul 22, 2025	Citigroup	Geoff Meacham—	-34.1%	$40 → $42	Maintained	Buy
Jul 10, 2025	Morgan Stanley	Terence Flynn—	-15.3%	$51 → $54	Maintained	Overweight
Oct 25, 2024	Citigroup	Andrew Baum—	-37.3%	$60 → $40	Maintained	Buy
Aug 14, 2024	Goldman Sachs	Chris Shibutani—	-20.0%	$50 → $51	Maintained	Buy
Jul 11, 2024	Morgan Stanley	Terence Flynn—	-20.0%	$48 → $51	Maintained	Overweight
Jun 3, 2024	UBS	Ashwani Verma—	-56.1%	$28	Downgrade	Buy→Neutral
Apr 12, 2024	B of A Securities	Geoff Meacham—	-40.4%	$40 → $38	Maintained	Buy
Feb 20, 2024	JP Morgan	Chris Schott—	-34.1%	$45 → $42	Maintained	Overweight
Feb 20, 2024	Goldman Sachs	Chris Shibutani—	-21.6%	$56 → $50	Maintained	Buy
Nov 9, 2023	Morgan Stanley	Terence Flynn—	-10.6%	$54 → $57	Maintained	Overweight